Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene

Parkinsonism and Related Disorders

Volumn 21, Issue 5, 2015, Pages 494-499

  Somme, Johanne Hatteland ^b   Molano Salazar, Ana ^a   Gonzalez, Amaia ^a   Tijero, Beatriz ^a   Berganzo, Koldo ^a   Lezcano, Elena ^a   Fernandez Martinez, Manuel ^a   Zarranz, Juan Jose ^a   Gómez Esteban, Juan Carlos ^a  

^a HOSPITAL DE CRUCES   (Spain)

^b HOSPITAL TXAGORRITXU   (Spain)

Author keywords

Cognitive impairment; Familial; LRRK2; Neuropsychiatry; Parkinson's disease; R1441G mutation

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; LEVODOPA; NEUROLEPTIC AGENT; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADULT; AGED; APATHY; ARTICLE; BEHAVIOR DISORDER; COGNITIVE DEFECT; DEMENTIA; EPISODIC MEMORY; FEMALE; GENE MUTATION; HALLUCINATION; HUMAN; IDIOPATHIC PARKINSON DISEASE; LRRK2 GENE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MILD COGNITIVE IMPAIRMENT; PARKINSON DISEASE; PRIORITY JOURNAL; UNIFIED PARKINSON DISEASE RATING SCALE; VERBAL MEMORY; BEHAVIOR; COGNITION DISORDERS; GENETICS; MIDDLE AGED; MUTATION;

AGED; BEHAVIORAL SYMPTOMS; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES;

EID: 84928584810     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.02.019     Document Type: Article

References (31)

1. Bonifati V. Genetics of Parkinson's disease-state of the art, 2013. Park Relat Disord 2014, 20(Suppl.1):S23-S28. 10.1016/S1353-8020(13)70009-9.
2. Simon-Sanchez J., Marti-Masso J.F., Sanchez-Mut J.V., Paisan-Ruiz C., Martinez-Gil A., Ruiz-Martinez J., et al. Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques. Mov Disord 2006, 21:1954-1959. 10.1002/mds.21114.
3. Healy D.G., Falchi M., O'Sullivan S.S., Bonifati V., Durr A., Bressman S., et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008, 7:583-590. 10.1016/S1474-4422(08)70117-0.
4. Ben Sassi S., Nabli F., Hentati E., Nahdi H., Trabelsi M., Ben Ayed H., et al. Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease. Park Relat Disord 2012, 18:243-246. 10.1016/j.parkreldis.2011.10.009.
5. Belarbi S., Hecham N., Lesage S., Kediha M.I., Smail N., Benhassine T., et al. LRRK2 G2019S mutation in Parkinson's disease: a neuropsychological and neuropsychiatric study in a large Algerian cohort. Park Relat Disord 2010, 16:676-679. 10.1016/j.parkreldis.2010.09.003.
6. Goldwurm S., Zini M., Di Fonzo A., De Gaspari D., Siri C., Simons E.J., et al. LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Park Relat Disord 2006, 12:410-419. 10.1016/j.parkreldis.2006.04.001.
7. Marras C., Schule B., Munhoz R.P., Rogaeva E., Langston J.W., Kasten M., et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 2011, 77:325-333. 10.1212/WNL.0b013e318227042d.
8. Wszolek Z.K., Pfeiffer B., Fulgham J.R., Parisi J.E., Thompson B.M., Uitti R.J., et al. Western Nebraska family (family D) with autosomal dominant parkinsonism. Neurology 1995, 45:502-505.
9. Nuytemans K., Rademakers R., Theuns J., Pals P., Engelborghs S., Pickut B., et al. Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients. Eur J Hum Genet 2008, 16:471-479. 10.1038/sj.ejhg.5201986.
10. Haugarvoll K., Rademakers R., Kachergus J.M., Nuytemans K., Ross O.A., Gibson J.M., et al. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 2008, 70:1456-1460. 10.1212/01.wnl.0000304044.22253.03.
11. Estanga A., Rodriguez-Oroz M.C., Ruiz-Martinez J., Barandiaran M., Gorostidi A., Bergareche A., et al. Cognitive dysfunction in Parkinson's disease related to the R1441G mutation in LRRK2. Park Relat Disord 2014, 20:1097-1100. 10.1016/j.parkreldis.2014.07.005.
12. Paisan-Ruiz C., Saenz A., Lopez de Munain A., Marti I., Martinez Gil A., Marti-Masso J.F., et al. Familial Parkinson's disease: clinical and genetic analysis of four Basque families. Ann Neurol 2005, 57:365-372. 10.1002/ana.20391.
13. Poulopoulos M., Cortes E., Vonsattel J.P., Fahn S., Waters C., Cote L.J., et al. Clinical and pathological characteristics of LRRK2 G2019S patients with PD. JMol Neurosci 2012, 47:139-143. 10.1007/s12031-011-9696-y.
14. Gomez A., Ferrer I. Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment. Acta Neuropathol 2010, 120:155-167. 10.1007/s00401-010-0669-y.
15. Marti-Masso J.F., Ruiz-Martinez J., Bolano M.J., Ruiz I., Gorostidi A., Moreno F., et al. Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2. Mov Disord 2009, 24:1998-2001. 10.1002/mds.22677.
16. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. JNeurol Neurosurg Psychiatr 1992, 55:181-184.
17. Tomlinson C.L., Stowe R., Patel S., Rick C., Gray R., Clarke C.E. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010, 25:2649-2653. 10.1002/mds.23429.
18. Gardner R., Oliver-Munoz S., Fisher L., Empting L. Mattis dementia rating scale: internal reliability study using a diffusely impaired population. JClin Neuropsychol 1981, 3:271-275.
19. Rey A. L'examen psychologique dans les cas d'encephalopathic traumatique. Arch Psychol 1941, 28:21.
20. Benton A.L. Avisual retention test for clinical use. Arch Neurol Psychiatry 1945, 54:212-216.
21. Benton A., Hannay H.J., Varney N.R. Visual perception of line direction in patients with unilateral brain disease. Neurology 1975, 25:907-910.
22. Cacho J., Garcia-Garcia R., Arcaya J., Gay J., Guerrero-Peral A.L., Gomez-Sanchez J.C., et al. The 'clock drawing test' in healthy elderly people. Rev Neurol 1996, 24:1525-1528.
23. Baldo J.V., Schwartz S., Wilkins D., Dronkers N.F. Role of frontal versus temporal cortex in verbal fluency as revealed by voxel-based lesion symptom mapping. JInt Neuropsychol Soc 2006, 12:896-900. 10.1017/S1355617706061078.
24. Emre M., Aarsland D., Brown R., Burn D.J., Duyckaerts C., Mizuno Y., et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007, 22:1689-1707. quiz 837. 10.1002/mds.21507.
25. Litvan I., Goldman J.G., Troster A.I., Schmand B.A., Weintraub D., Petersen R.C., et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: movement disorder society task force guidelines. Mov Disord 2012, 27:349-356. 10.1002/mds.24893.
26. Cummings J.L. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997, 48:S10-S16.
27. Perneger T.V. What's wrong with Bonferroni adjustments. BMJ 1998, 316:1236-1238.
28. Alcalay R.N., Mejia-Santana H., Tang M.X., Rakitin B., Rosado L., Ross B., et al. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. JClin Exp Neuropsychol 2010, 32:775-779. 10.1080/13803390903521018.
29. Alcalay R.N., Mirelman A., Saunders-Pullman R., Tang M.X., Mejia Santana H., Raymond D., et al. Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. Mov Disord 2013, 28:1966-1971. 10.1002/mds.25647.
30. Lesage S., Ibanez P., Lohmann E., Pollak P., Tison F., Tazir M., et al. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 2005, 58:784-787. 10.1002/ana.20636.
31. Brockmann K., Groger A., Di Santo A., Liepelt I., Schulte C., Klose U., et al. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Mov Disord 2011, 26:2335-2342. 10.1002/mds.23991.